APLM Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 145328 min ago

@ $0.675

Wydano: 9 vas. 2024 @ 16:59

Zwrot: -50.75%

Poprzedni sygnał: vas. 7 - 16:54

Poprzedni sygnał: Sprzedaż

Zwrot: 4.44 %

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia...

Stats
Dzisiejszy wolumen	105 276
Średni wolumen	178 103
Kapitalizacja rynkowa	29.73M
EPS	$0 ( 2024-04-26 )
Następna data zysków	( $0 ) 2024-06-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0.00400 (1.20%)

Wolumen Korelacja

Długi: -0.17 (neutral)

Krótki: -0.39 (neutral)

Signal:(47.318) Neutral

Apollomics, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Apollomics, Inc. Korelacja - Waluta/Towar

0.03
( neutral )

-0.01
( neutral )

0.00
( neutral )

0.14
( neutral )

Apollomics, Inc. Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-2.77

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-2.77

Financial Reports:

No articles found.

Apollomics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Apollomics, Inc.

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.